Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3357

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3357
---
 Jack A. Elias and Dr. Jonathan Kurtis, are both affiliated with Brown University and with Rhode Island
Hospital.

9

Our
Pipeline

Our
pipeline consists of preclinical programs. We anticipate moving certain preclinical product candidates in our oncology, fibrosis and/or
infectious disease platforms, all licensed exclusively from Brown University and Rhode Island Hospital, into the clinic in the next 12
to 18 months.

Our
programs in oncology and fibrosis are based on discoveries of disease pathways and of related drug targets emerging from pioneering work
in the field of chitinase biology by our scientific co-founder and member of our board of directors, Jack A. Elias, M.D., former Dean
of Medicine and current Special Advisor for Health Affairs to Brown University.

In
oncology, our product candidates are based on Dr. Elias’ findings that a protein called chitinase 3-like-1, or Chi3L1, is a key
driver of multiple disease pathways, including those involved in primary and metastatic tumor development. In animal models of both lung
cancer and glioblastoma, inhibition of Chi3l1 resulted in significant tumor reduction, and the reduction was even greater when the inhibition
of Chi3l1 was combined with immune checkpoint inhibitors, which are used as immuno-therapies to stimulate the body’s immune response
against cancer. Neutralizing antibodies against Chi3l1 have been developed that are highly avid, specific, react with mouse, human and
monkey Chi3l1 and are effectively expressed and humanized. We are developing a mono-specific antibody, or mAb, and two bi-specific monoclonal
antibodies, or BsAbs, product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer, or NSCLC, which affects approximately
460,000 people in the United States, and of glioblastoma multiforme, or GBM, a usually lethal form of brain cancer that affects approximately
28,000 people in the United States. The median survival for individuals diagnosed with GBM is approximately 15 months and the five year
survival rate is just 8% for those aged 45-54 and 5% for those aged 55-64.

Our
product candidate in fibrosis is based on a drug target investigated by Dr. Elias and closely related to the Chi3l1 oncology target described
above. Dr. Elias found that an enzyme called chitin